Aytu BioPharma Inc./$AYTU
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Aytu BioPharma Inc.
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline, including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates one business segment consisting of various prescription pharmaceutical products sold through third parties.
Ticker
$AYTU
Sector
Primary listing
Employees
83
Headquarters
Website
AYTU Metrics
BasicAdvanced
$23M
-
-$2.16
0.28
-
Price and volume
Market cap
$23M
Beta
0.28
52-week high
$2.82
52-week low
$0.95
Average daily volume
300K
Financial strength
Current ratio
1.256
Quick ratio
0.985
Long term debt to equity
62.638
Total debt to equity
120.937
Interest coverage (TTM)
0.69%
Profitability
EBITDA (TTM)
7.914
Gross margin (TTM)
69.04%
Net profit margin (TTM)
-20.43%
Operating margin (TTM)
3.82%
Effective tax rate (TTM)
-3.18%
Revenue per employee (TTM)
$800,000
Management effectiveness
Return on assets (TTM)
1.31%
Return on equity (TTM)
-60.76%
Valuation
Price to revenue (TTM)
0.223
Price to book
1.12
Price to tangible book (TTM)
-0.91
Price to free cash flow (TTM)
-2.869
Free cash flow yield (TTM)
-34.85%
Free cash flow per share (TTM)
-0.822
Growth
Revenue change (TTM)
1.84%
Earnings per share change (TTM)
-24.51%
3-year revenue growth (CAGR)
-11.78%
10-year revenue growth (CAGR)
73.94%
3-year earnings per share growth (CAGR)
-69.21%
AYTU News
AllArticlesVideos
Aytu BioPharma to Present at Upcoming October 2025 Conferences
Accesswire3 days ago
Aytu BioPharma to Present at Upcoming September 2025 Conferences
Accesswire3 weeks ago
Aytu BioPharma Reports Fiscal 2025 Full Year and Fourth Quarter Operational and Financial Results and Outlines Commercial Launch Plans for EXXUA(TM)
Accesswire3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Aytu BioPharma Inc. stock?
Aytu BioPharma Inc. (AYTU) has a market cap of $23M as of October 13, 2025.
What is the P/E ratio for Aytu BioPharma Inc. stock?
The price to earnings (P/E) ratio for Aytu BioPharma Inc. (AYTU) stock is 0 as of October 13, 2025.
Does Aytu BioPharma Inc. stock pay dividends?
No, Aytu BioPharma Inc. (AYTU) stock does not pay dividends to its shareholders as of October 13, 2025.
When is the next Aytu BioPharma Inc. dividend payment date?
Aytu BioPharma Inc. (AYTU) stock does not pay dividends to its shareholders.
What is the beta indicator for Aytu BioPharma Inc.?
Aytu BioPharma Inc. (AYTU) has a beta rating of 0.28. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.